BAVA:VIE
Bavarian Nordic A/S
€31.74
arrow_upward
+0.13%(+0.040) 1 دن
14 اکتوبر, 11:00:22 AM GMT +2 · EUR
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoBAVA کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
€31.66
اعلی
€31.74
کم
€31.66
مارکیٹ کی سرمایہ کاری
2.82 ارب
اوسط والیوم
17.00
والیوم
0.00
52 ہفتے میں اعلی
€32.47
52 ہفتے کا کم
€22.96
ملازمین کی تعداد
2 ہزار
کھولیں
€31.66
اعلی
€31.74
کم
€31.66
مارکیٹ کی سرمایہ کاری
2.82 ارب
اوسط والیوم
17.00
والیوم
0.00
52 ہفتے میں اعلی
€32.47
52 ہفتے کا کم
€22.96
ملازمین کی تعداد
2 ہزار
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
GlobeNewswire
·
22 منٹ پہلے
Owlting Group (NASDAQ: OWLS) and Decaf Open U.S. Dollar Accounts Beyond the United States on OwlPay Harbor
Reuters
·
15 منٹ پہلے
Mapping the Market: Dow eyes another run at a rally
Investor's Business Daily
·
51 منٹ پہلے
Dow Futures Rise; ASML Earnings Beat, CPI Inflation Due
Seeking Alpha
·
3 گھنٹے پہلے
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
پروفائل
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Bavarian Nordic A/S کے بارے میں